TY - JOUR
T1 - Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients
AU - Fumagalli, Caterina
AU - Pruneri, Giancarlo
AU - Possanzini, Paola
AU - Manzotti, Michela
AU - Barile, Monica
AU - Feroce, Irene
AU - Colleoni, Marco
AU - Bonanni, Bernardo
AU - Maisonneuve, Patrick
AU - Radice, Paolo
AU - Viale, Giuseppe
AU - Barberis, Massimo
PY - 2012/7
Y1 - 2012/7
N2 - Triple-negative breast cancers are characterized by the triple-negative (ER/PgR/Her2 negative) phenotype, are frequently associated with BRCA gene mutation, and are not candidate to currently available endocrine and HER2-targeted treatments. MGMT is involved in direct DNA repair exerted by cleavage of mutagenic alkyl adducts within DNA, and its epigenetic silencing confers susceptibility to DNA-damaging alkylating agents in glioblastomas and melanomas. MGMT methylation status has not been extensively investigated in breast cancer patients. The goal of our study was to evaluate the MGMT methylation status in TNBC patients, for most of which BRCA1 and BRCA2 mutational status was known. We evaluated MGMT methylation status by methylation-specific PCR (MSP) in formalin-fixed and paraffin-embedded tumor specimens from 92 TNBC patients. By using the GelDoc system (Biorad) software, the cases were further classified as follows: 0 (absence of methylated signal), 1 (prevalence of unmethylated signal, U/M ratio >1), 2 (prevalence of methylated signal, U/M ratio
AB - Triple-negative breast cancers are characterized by the triple-negative (ER/PgR/Her2 negative) phenotype, are frequently associated with BRCA gene mutation, and are not candidate to currently available endocrine and HER2-targeted treatments. MGMT is involved in direct DNA repair exerted by cleavage of mutagenic alkyl adducts within DNA, and its epigenetic silencing confers susceptibility to DNA-damaging alkylating agents in glioblastomas and melanomas. MGMT methylation status has not been extensively investigated in breast cancer patients. The goal of our study was to evaluate the MGMT methylation status in TNBC patients, for most of which BRCA1 and BRCA2 mutational status was known. We evaluated MGMT methylation status by methylation-specific PCR (MSP) in formalin-fixed and paraffin-embedded tumor specimens from 92 TNBC patients. By using the GelDoc system (Biorad) software, the cases were further classified as follows: 0 (absence of methylated signal), 1 (prevalence of unmethylated signal, U/M ratio >1), 2 (prevalence of methylated signal, U/M ratio
KW - BRCA1
KW - MGMT
KW - Triple negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84863988129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863988129&partnerID=8YFLogxK
U2 - 10.1007/s10549-011-1945-9
DO - 10.1007/s10549-011-1945-9
M3 - Article
C2 - 22228432
AN - SCOPUS:84863988129
VL - 134
SP - 131
EP - 137
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 1
ER -